%0 Journal Article %T Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes %A Tovilla-Zárate, Carlos Alfonso %A Pérez-Mandujano, Antonia %A Ramírez-González, Iris Rubí %A Fresan, Ana %A Suarez-Mendez, Samuel %A Martínez-Villaseñor, Esteban %A Rodríguez-Sánchez, Ester %A Villar-Soto, Mario %A López-Narváez, María Lilia %A González-Castro, Thelma Beatriz %A Ble-Castillo, Jorge L. %A Juárez-Rojop, Isela Esther %J Annals of Translational Medicine %D 2019 %B 2019 %9 %! Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes %K %X Background: Depression in patients with type 2 diabetes (T2D) is often undiagnosed and remains untreated, leading to poor therapy adherence and ill health-related outcomes. We evaluated the effect of vortioxetine versus sertraline in the treatment of depression, distress and metabolic control in subjects with T2D and depression. Methods: Participants were selected from the Clinic for Diabetes, diagnosed with depression when the score was ≥14 in the Hamilton Depression Rating Scale, and verified by a psychiatrist in agreement with the DSM-5 instrument (Diagnostic and Statistical Manual of Mental Disorders, fifth edition). The criteria for recruitment also included glycosylated hemoglobin ≥7.5%, 18 to 60 years of age, and written informed consent. Pharmacological treatment for depression was assigned randomly: vortioxetine (10 mg/day) or sertraline (75 mg/day) for 8 weeks. Biochemical parameters, anthropometric measures and depression symptoms were evaluated after antidepressant treatment. This was a randomized singled-blind study. Results: Subjects that met the inclusion criteria were 50, of which only 21 patients with T2D and depression finished the treatment. Vortioxetine and sertraline showed partial remission of depression. Vortioxetine showed a major effect size in glycosylated hemoglobin and a moderate effect size on weight loss, fasting plasma glucose (FPG), cholesterol and triacylglycerol levels. On the other hand, patients treated with sertraline presented a slight increase in body weight, body mass index (BMI), and in all biochemical markers. Conclusions: Vortioxetine may ameliorate depressive symptoms and metabolic control in patients with T2D and depression. Trial registration number: NCT03978286. %U https://atm.amegroups.org/article/view/30925 %V 7 %N 22 %P 656 %@ 2305-5847